BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
BiondVax Pharmaceuticals Stock Performance
Shares of NASDAQ:BVXV traded down $0.03 during midday trading on Wednesday, hitting $1.21. The stock had a trading volume of 7 shares, compared to its average volume of 30,346. The company's 50-day moving average price is $1.21 and its 200-day moving average price is $1.32. BiondVax Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $3.49. The company has a debt-to-equity ratio of 4.03, a current ratio of 5.82 and a quick ratio of 5.82.
BiondVax Pharmaceuticals (NASDAQ:BVXV - Get Rating) last released its quarterly earnings data on Wednesday, June 1st. The company reported ($0.20) earnings per share (EPS) for the quarter. Research analysts predict that BiondVax Pharmaceuticals will post -0.02 EPS for the current year.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on shares of BiondVax Pharmaceuticals in a research report on Wednesday. They issued a "sell" rating for the company.